Business
Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights
– Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO –– Recently expanded ANX005 clinical program into neurodegeneration, with
About this update from Annexon, Inc.
[{"type":"text","content":"– Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO –– Recently expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Huntington’s Disease –– Fully enrolled Phase 1b DDI trial in Guillain-Barré Syndrome –\n SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye, today announced third quarter 2020 financial results and recent business highlights. “We continue to make strong progress across our classical complement platform, including expanded development of ANX005 in Huntington’s Disease, and advancement of our subcutaneous formulation, ANX009, into the clinic,” said Douglas Love, Esq., president and chief executive officer of Annexon. “Our unique focus on C1q allows us to address a diverse set of classical complement-mediated autoimmune and neurodegenerative diseases, and we’re well capitalized to conduct several promising near- and mid-term Phase 2 clinical trials in these devastating diseases.” Program Highlights Initiated Phase 2 trial evaluating ANX005 in Huntington’s Disease (HD). Initiated patient dosing in a Phase 2 trial designed to assess safety, tolerability, and biomarkers of target engagement and impact on neurodegenerationInitiated Phase 1 first-in-human trial of ANX009. Initiated subcutaneous dosing of healthy volunteers with Annexon’s third clinical-stage drug candidate in a Phase 1 trial designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending dosesCompleted enrollment of Guillain-Barré Syndrome (GBS) Drug-Drug Interaction (DDI) trial. Fully enrolled global Phase 1b DDI trial assessing safety and potential pharmacokinetic effect of ANX005 co-administered with IVIg in GBS patients. Data are anticipated in early 2021 Anticipated Upcoming Milestones ANX005, a clinical-stage investigational monoclonal antibody intended to treat patients with complement-mediated disorders-- Phase 2 trial in patients with HD is ongoing with initial data anticipated in 2H 2021-- Phase 2/3 trial in patients with GBS is planned to initiate in early 2021 with data anticipated in 2023-- Phase 2 trial in patients...